A Phase II Study of AT-101 to Overcome Bcl-2-Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer.

We conducted a phase II study in men with castration-sensitive metastatic prostate cancer to test the hypothesis that AT-101, a small molecule Bcl-2 inhibitor, has clinical activity in patients initiating androgen deprivation therapy (ADT) for metastatic prostate cancer.

Patients with metastatic prostate cancer scheduled to start, or who had recently (within 6 weeks) initiated, ADT were enrolled. ADT with a luteinizing hormone-releasing hormone agonist and bicalutamide was started 6 weeks before initiation of oral AT-101, 20 mg/day for 21 days of a 28-day cycle. The primary endpoint of the study was the percentage of patients with an undetectable prostate-specific antigen (PSA) level (≤ 0. 2 ng/mL) after 7. 5 months (1. 5 months of ADT alone plus 6 months of combined ADT and AT-101). To assess for an association between chromodomain helicase DNA binding protein 1 (CHD1) and drug sensitivity, fluorescence in situ hybridization with confocal microscopy was assessed in a subgroup of patients.

A total of 55 patients were enrolled, with median age of 61 years and a median PSA level of 27. 6 ng/dL. Of the 55 patients, 72% had a Gleason score ≥ 8. Three patients had visceral metastases, and the remaining patients had bone or nodal metastasis. An undetectable PSA level was achieved in 31% of the patients. Of the 31 patients, 12 experienced serious adverse events, 7 of which were considered related to study therapy. Most of the related adverse events were gastrointestinal and nervous system disorders. CHD1 assessment was feasible, with a nonsignificant association with therapeutic sensitivity in a small number of patients.

The combination of ADT and AT-101 did not meet the prespecified level of activity for further development of this combination.

Clinical genitourinary cancer. 2015 Sep 21 [Epub ahead of print]

Mark N Stein, Maha Hussain, Walter M Stadler, Glenn Liu, Irina V Tereshchenko, Susan Goodin, Chandrika Jeyamohan, Howard L Kaufman, Janice Mehnert, Robert S DiPaola

Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. , University of Michigan, Ann Arbor, MI. , University of Chicago, Chicago, IL. , UW Carbone Cancer Center, University of Wisconsin, Madison, WI. , Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. , Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. , Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. , Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. , Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. , Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. 

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe